CC
MRNA icon

Centiva Capital’s Moderna MRNA Stock Holding History

Centiva Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-134,800
Closed -$6.85M – 2096
2026
Q1 		$6.85M Buy
+134,800
New +$6.29M 0.05% 239
2025
Q3 		– Sell
-150,000
Closed -$4.14M – 1574
2025
Q2 		$4.14M Buy
+150,000
New +$3.95M 0.07% 173
2024
Q4 		– Sell
-5,100
Closed -$341K – 2142
2024
Q3 		$341K Buy
5,100
+1,500
+42% +$138K 0.01% 1501
2024
Q2 		$428K Buy
+3,600
New +$456K 0.01% 1253
2024
Q1 		– Sell
-5,000
Closed -$497K – 2062
2023
Q4 		$497K Buy
+5,000
New +$421K 0.01% 964
2023
Q3 		– Sell
-22,500
Closed -$2.73M – 1952
2023
Q2 		$2.73M Sell
22,500
-12,900
-36% -$1.72M 0.06% 302
2023
Q1 		$5.44M Buy
35,400
+300
+0.9% +$49.5K 0.13% 161
2022
Q4 		$6.3M Sell
35,100
-21,500
-38% -$3.52M 0.18% 111
2022
Q3 		$6.7M Sell
56,600
-22,000
-28% -$3.34M 0.13% 113
2022
Q2 		$11.2M Buy
78,600
+29,000
+58% +$4.15M 0.27% 43
2022
Q1 		$8.54M Sell
49,600
-25,000
-34% -$4.21M 0.16% 81
2021
Q4 		$18.9M Buy
74,600
+68,830
+1,193% +$20.1M 0.39% 43
2021
Q3 		$2.22M Sell
5,770
-70,030
-92% -$25.8M 0.14% 154
2021
Q2 		$17.8M Buy
75,800
+13,500
+22% +$2.41M 0.42% 35
2021
Q1 		$8.16M Buy
+62,300
New +$9.03M 0.31% 55

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Centiva Capital's MRNA Position: Q2 2026 in Review

Centiva Capital sold out of Moderna (MRNA) in Q2 2026, closing a stake of 2,733 shares — an estimated $139K sold.

Centiva Capital first reported a position in MRNA in Q2 2020 and held it in 15 quarters. The position peaked at $5.92M in Q1 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Centiva Capital reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 2,733 Moderna shares in Q2 2026, an estimated $139K.
  • Centiva Capital first reported a position in Moderna in Q2 2020 and held it in 15 quarters.
  • Centiva Capital's Moderna position peaked at $5.92M in Q1 2022.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.